Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
- Author(s)
- da Silva, IP; Ahmed, T; Reijers, ILM; Warner, AB; Patrinely, JR; Serra-Bellver, P; Allayous, C; Mangana, J; Zimmer, L; Trojaniello, C; Klein, O; Gerard, CL; Michielin, O; Haydon, A; Ascierto, PA; Carlino, MS; Lebbe, C; Lorigan, P; Johnson, DB; Sandhu, S; Lo, SN; Menzies, AM; Long, GV;
- Details
- Publication Year 2021-08,Volume 22,Issue #8,Page e343-e344
- Journal Title
- Lancet Oncology
- Publication Type
- Correspondence
- Keywords
- Humans; Ipilimumab/adverse effects; *Melanoma/drug therapy; Nivolumab/adverse effects
- Department(s)
- Medical Oncology
- PubMed ID
- 34339647
- Publisher's Version
- https://doi.org/10.1016/S1470-2045(21)00419-8
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-09-05 04:42:41
Last Modified: 2025-09-05 04:44:09